SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Sonus Networks (Nasdaq: SONS) $3.03. Announced Monday after market close results for the fourth quarter and full year ended December 31, 2010. Revenue for the fourth quarter of 2010 was $83.0 million, compared to $42.7 million in the third quarter of 2010 and $68.7 million for the fourth quarter of 2009. The Company's net income on a GAAP basis for the fourth quarter of 2010 was $11.4 million, or $0.04 per diluted share, compared to a net loss of $22.3 million, or $0.08 per share, for the third quarter of 2010, and net income of $10.3 million, or $0.04 per diluted share, for the fourth quarter of 2009.
Gross profit on a non-GAAP basis for 2010 was $155.5 million, compared to $146.5 million for 2009, reflecting a year-over-year increase of $9.0 million. Operating expenses on a non-GAAP basis for 2010 were $149.5 million, compared to $141.3 million for 2009. The Company's net income on a non-GAAP basis for 2010 was $6.8 million, or $0.02 per diluted share, compared to net income of $11.6 million, or $0.04 per diluted share, for 2009.
What They Do: Sonus Networks, Inc. is a leader in IP networking with proven expertise in delivering secure, reliable and scalable next generation infrastructure and subscriber solutions.
Novavax, Inc. (Nasdaq: NVAX) $2.60. Today announced an agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to LG Life Sciences, Ltd. (LGLS). Under the agreement, LGLS receives an exclusive license to manufacture, develop and commercialize influenza vaccines using Novavax's recombinant VLP technology in South Korea. LGLS also receives a non-exclusive license to manufacture, develop and commercialize influenza VLP vaccines in certain emerging market countries.
LGLS will be responsible for funding clinical development and licensure of influenza VLP vaccines in South Korea and other countries, and for construction of a new VLP vaccine manufacturing facility planned at LGLS's Osong campus in South Korea. Novavax will receive upfront and milestone payments from LGLS in addition to double-digit royalty rate payments from commercial sales. Novavax will provide VLP technology transfer and manufacturing support for LGLS's new vaccine production facility.
What They Do: Novavax, Inc. is a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV).
SodaStram International (Nasdaq: SODA) $44.23. Today announced its results for the three and twelve month periods ended December 31, 2010. Fourth Quarter Financial Highlights. Revenues increased 59% to euro 50.0 million. Americas revenues increased 238% to euro 14.5 million. Western Europe revenues increased 24% to euro 25.4 million. Diluted earnings per share was euro 0.21 or $0.28. Soda maker unit sales increased 85% to 712,000.
Total revenues for the twelve months ended December 31, 2010 increased 53.0% to euro 160.7 million or $213.2 million per the convenience translation, compared to euro 105.0 million for the comparable period in 2009. Sales increased in each geographical region year-over-year, with revenues for Western Europe and the Americas increasing 34.0% and 188.9%, respectively, compared to the same period in 2009.
For the full year, the Company sold 1,922,000 soda makers compared to 1,057,000 in 2009, an 81.9% increase, and sold 9.8 million CO2 refills during 2010 compared to 8.2 million CO2 refills in 2009.
What They Do: SodaStream manufactures home beverage carbonation systems, which enable consumers to easily transform ordinary tap water instantly into carbonated soft drinks and sparkling water.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
